Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

David Lewinsohn, Raleigh A. Bowden, Debra Mattson, Stephen W. Crawford

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects. Since there is lack of proven efficacy and safety of the aerosolized ribavirin in this setting, we performed a phase I study of intravenous ribavirin treatment. Between November 1993 and May 1994, 10 patients with clinically significant RSV pneumonia at the Fred Hutchinson Cancer Research Center were enrolled. Only 2 of the 10 survived (20%; 95% CI, 3-56). Two of the 10 patients developed acute hemolysis that necessitated discontinuation of the medication. In conclusion, treatment of marrow transplant recipients with RSV pneumonia with intravenous ribavirin did not improve mortality compared with historical controls treated with the aerosolized drug.

Original languageEnglish (US)
Pages (from-to)2555-2557
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume40
Issue number11
StatePublished - Nov 1996
Externally publishedYes

Fingerprint

Respiratory Syncytial Viruses
Ribavirin
Pneumonia
Transplantation
Bone Marrow
Pharmaceutical Preparations
Therapeutics
Mortality
Hemolysis
Nucleosides
Caregivers
Safety
Research
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. / Lewinsohn, David; Bowden, Raleigh A.; Mattson, Debra; Crawford, Stephen W.

In: Antimicrobial Agents and Chemotherapy, Vol. 40, No. 11, 11.1996, p. 2555-2557.

Research output: Contribution to journalArticle

@article{3c776b8486444e2d9f9827ac6cf40a26,
title = "Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation",
abstract = "Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects. Since there is lack of proven efficacy and safety of the aerosolized ribavirin in this setting, we performed a phase I study of intravenous ribavirin treatment. Between November 1993 and May 1994, 10 patients with clinically significant RSV pneumonia at the Fred Hutchinson Cancer Research Center were enrolled. Only 2 of the 10 survived (20{\%}; 95{\%} CI, 3-56). Two of the 10 patients developed acute hemolysis that necessitated discontinuation of the medication. In conclusion, treatment of marrow transplant recipients with RSV pneumonia with intravenous ribavirin did not improve mortality compared with historical controls treated with the aerosolized drug.",
author = "David Lewinsohn and Bowden, {Raleigh A.} and Debra Mattson and Crawford, {Stephen W.}",
year = "1996",
month = "11",
language = "English (US)",
volume = "40",
pages = "2555--2557",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

AU - Lewinsohn, David

AU - Bowden, Raleigh A.

AU - Mattson, Debra

AU - Crawford, Stephen W.

PY - 1996/11

Y1 - 1996/11

N2 - Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects. Since there is lack of proven efficacy and safety of the aerosolized ribavirin in this setting, we performed a phase I study of intravenous ribavirin treatment. Between November 1993 and May 1994, 10 patients with clinically significant RSV pneumonia at the Fred Hutchinson Cancer Research Center were enrolled. Only 2 of the 10 survived (20%; 95% CI, 3-56). Two of the 10 patients developed acute hemolysis that necessitated discontinuation of the medication. In conclusion, treatment of marrow transplant recipients with RSV pneumonia with intravenous ribavirin did not improve mortality compared with historical controls treated with the aerosolized drug.

AB - Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects. Since there is lack of proven efficacy and safety of the aerosolized ribavirin in this setting, we performed a phase I study of intravenous ribavirin treatment. Between November 1993 and May 1994, 10 patients with clinically significant RSV pneumonia at the Fred Hutchinson Cancer Research Center were enrolled. Only 2 of the 10 survived (20%; 95% CI, 3-56). Two of the 10 patients developed acute hemolysis that necessitated discontinuation of the medication. In conclusion, treatment of marrow transplant recipients with RSV pneumonia with intravenous ribavirin did not improve mortality compared with historical controls treated with the aerosolized drug.

UR - http://www.scopus.com/inward/record.url?scp=0029970801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029970801&partnerID=8YFLogxK

M3 - Article

C2 - 8913463

AN - SCOPUS:0029970801

VL - 40

SP - 2555

EP - 2557

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -